You are here: Industry Insights > VXA-CoV2-1

News List

Vaxart’s Covid-19 vaccine shows cross-coronavirus activity in trial pharmaceutical-technology
May 06, 2021
Vaxart has reported the latest data from the Phase I trial of its first Covid-19 oral vaccine construct, VXA-CoV2-1, which showed broad cross-reactivity against other coronaviruses.
Vaxart’s oral vaccine candidate triggers immune response in Covid-19 trial pharmaceutical-technology
February 05, 2021
Vaxart has reported preliminary data from its Phase I study that showed its oral Covid-19 tablet vaccine candidate, VXA-CoV2-1, triggered multiple immune responses against SARS-CoV-2 antigens.
Vaxart Oral COVID-19 Vax Tablet Shows Promise contractpharma
February 04, 2021
Phase I study reached primary and secondary endpoints of safety and immunogenicity.
First patient dosed in COVID-19 vaccine tablet clinical trial europeanpharmaceuticalreview
October 16, 2020
A Phase I clinical trial to test VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate, has been initiated with the first patient dosed.